Published in:
Open Access 01-12-2018 | Letter to the Editor
The addition of avibactam renders piperacillin an effective treatment for Mycobacterium abscessus infection in an in vivo model
Published in: Antimicrobial Resistance & Infection Control | Issue 1/2018
Login to get accessAbstract
Treating M. abscessus infection is challenging due to the potent β-lactamase BlaMab (Beta-lactamase of M. abscessus). Avibactam is a non-β-lactam, β-lactamase inhibitor shown to inhibit BlaMab. We tested whether avibactem can render piperacillin effective against M. Abscessus. In-vitro, avibactam enhanced the activity of piperacillin by 16–32 fold, with no significant effect on meropenem. In an in-vivo Galleria mellonella model, meropenem and piperacillin/avibactam significantly decreased infection burden compared to untreated controls. Neither piperacillin nor avibactam alone had a significant effect.